INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines

/EIN News/ -- NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of ADMS and EXC. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you take no action, you may remain an absent class member. 

To discuss the cases below please contact Matthew E. Guarnero toll free at (877) 779-1414.

Adamas Pharmaceuticals  (NASDAQ: ADMS)
CLASS PERIOD: 08/08/2017-09/30/2019
LEAD PLAINTIFF DEADLINE: February 10, 2020

Defendants made materially false and misleading statements about: (1) managed care’s acceptance of GOCOVRI; (2) the breadth of insurer coverage for GOCOVRI prescriptions; and (3) the impact of the Company’s commercialization efforts. In addition, it is alleged that Defendants failed to disclose: (1) that health insurers were excluding GOCOVRI from their prescription formularies or requiring patients to use “step therapy” – i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) that the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) that, as a result of the foregoing, the Company’s financial statements and Defendants’ statements about Adamas’s business, operations, and prospects, were materially false and misleading at all relevant times.

To get additional information about the Adamas Shareholder Class Action contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com

Exelon Corporation (NASDAQ: EXC)
CLASS PERIOD: 02/09/2019-11/1/2019
LEAD PLAINTIFF DEADLINE: February 14, 2020

Defendants made materially false and misleading statements about: (i) Exelon and/or its employees were engaged in unlawful lobbying activities; (ii) the foregoing increased the risk of a criminal investigation into Exelon; (iii) ComEds revenues were in part the product of unlawful conduct and thus unsustainable; and (iv) that, as a result, the Company’s public statements were materially false and misleading at all relevant times.

To get additional information about the Exelon Shareholder Class Action contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com

ATTORNEY ADVERTISING. © 2019 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Matthew E. Guarnero
Bernstein Liebhard LLP
http://www.bernlieb.com   
(877) 779-1414
MGuarnero@bernlieb.com